Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Feb;184(4):690-693.
doi: 10.1111/bjh.15169. Epub 2018 Mar 12.

Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant

Deepika S Darbari  1   2   3   4 , Jaquette Liljencrantz  4   5 , Austin Ikechi  6 , Staci Martin  4   7 , Marie Claire Roderick  4   7 , Courtney D Fitzhugh  3   4 , John F Tisdale  4   8 , Swee Lay Thein  3   4 , Matthew Hsieh  4   8
Affiliations
Clinical Trial

Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant

Deepika S Darbari et al. Br J Haematol. 2019 Feb.
No abstract available

Keywords: haematopoietic stem cell transplant; opioids; pain; sickle cell disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests

None.

Figures

Fig 1.
Fig 1.
Opioid use pre- and post-HSCT by AAPT pain categories. *3 patients in acute episodic pain group had not reported using opioids. **1 patient in acute episodic pain group was on long acting opioids intermittently. AAPT, ACTTION-American Pain Society Pain Taxonomy diagnostic criteria for chronic SCD pain; AAPT subtype 1, Chronic SCD pain without contributory disease complications was used if there was no evidence of contributory SCD complications based on either clinical signs (e.g., presence of leg ulcers) or test results (e.g., imaging abnormalities); AAPT subtype 2, Chronic SCD pain with contributory disease complications was used if there was evidence of contributory SCD complications based on clinical signs or test results; AAPT subtype 3, Chronic SCD pain with mixed pain types was used if there was evidence of contributory SCD complications (e.g., avascular necrosis) based on clinical signs or test results and there was also pain occurring in unrelated sites (e.g., arms, back, chest, or abdominal pain); HSCT, hematopoietic stem cell transplant; LA Opioids, Long acting opioids; SA Opioids, Short acting opioids; SCD, sickle cell disease.
See this image and copyright information in PMC

References

    1. Beverung LM, Varni JW & Panepinto JA (2015) Clinically meaningful interpretation of pediatric health-related quality of life in sickle cell disease. Journal of Pediatric Hematology/Oncology, 37, 128–133. - PMC - PubMed
    1. Campbell CM, Moscou-Jackson G, Carroll CP, Kiley K, Haywood C Jr Lanzkron S, Hand M, Edwards RR & Haythornthwaite JA (2016) An evaluation of central sensitization in patients with sickle cell disease. The Journal of Pain, 17, 617–627. - PMC - PubMed
    1. Carroll CP, Lanzkron S, Haywood C Jr, Kiley K, Pejsa M, Moscou-Jackson G, Haythornth-waite JA & Campbell CM (2016) Chronic opioid therapy and central sensitization in sickle cell disease. American Journal of Preventive Medicine, 51, S69–S77. - PMC - PubMed
    1. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, Ader D, Fries JF, Bruce B & Rose M (2007) The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Medical Care, 45, S3–S11. - PMC - PubMed
    1. Dampier C, Palermo TM, Darbari DS, Hassell K, Smith W & Zempsky W (2017) AAPT diagnostic criteria for chronic sickle cell disease pain. The Journal of Pain, 18, 490–498. - PubMed

Substances